Physician profile
Davendra P Ramkumar
NPI 1063420370
$11,345.02
in general payments reported to CMS, 2019-2025
37 companies · $1,621 in 2025
The $1,621 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,601 · 2020: $855 · 2021: $1,220 · 2022: $2,110 · 2023: $2,148 · 2024: $1,789 · 2025: $1,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,517 · Education: $40.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,517.42 |
| Education | $40.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,088.72 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,576.69 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $1,132.79 | 2020-2025 | Stelara, Tremfya, Simponi |
| Nestle Healthcare Nutrition INC. | $534.64 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $501.27 | 2024-2025 | Zenpep, Vowst |
| Pfizer INC. | $499.45 | 2019-2025 | |
| Celgene Corporation | $361.67 | 2021-2023 | Zeposia |
| Ardelyx, INC. | $271.52 | 2022-2025 | Ibsrela |
| Ucb, INC. | $251.52 | 2019-2024 | Cimzia |
| Qol Medical, LLC | $241.60 | 2023-2024 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $205.08 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.79 | 2019-2022 | |
| Organon LLC | $169.04 | 2021-2024 | Hadlima, Renflexis |
| Intercept Pharmaceuticals, INC. | $159.07 | 2019-2025 | |
| Allergan, INC. | $126.11 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $116.19 | 2021-2025 | Rebyota |
| Phathom Pharmaceuticals, INC. | $103.05 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $88.72 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $85.44 | 2022 | |
| Ironwood Pharmaceuticals, INC | $85.40 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $80.57 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $80.30 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $62.38 | 2024-2025 | Iqirvo |
| Daiichi Sankyo INC. | $46.47 | 2019-2023 | Injectafer |
| Fresenius Kabi USA, LLC | $45.01 | 2023 | |
| Shire North American Group INC | $36.63 | 2019 | |
| Medtronic, INC. | $29.26 | 2025 | Pillcam |
| Genzyme Corporation | $23.85 | 2023 | |
| Novo Nordisk INC | $21.00 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $20.71 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $18.60 | 2024 | Cologuard Collection Kit |
| Ethicon US, LLC | $18.45 | 2020 | |
| Biocon Biologics INC | $18.39 | 2025 | Yesintek |
| Mauna Kea Technologies, INC. | $16.13 | 2019 | |
| Shionogi INC | $15.28 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $14.61 | 2023 | Dupixent |
| Alfasigma USA, INC. | $12.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davendra Ramkumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.